Prospective observational study evaluating serum GDF-15 levels in patients with acute pulmonary embolism.
Prospective observational study evaluating serum GDF-15 levels in patients with acute pulmonary embolism (APE). In APE right ventricle failure developing due to ischemia and myocarditis is considered the primary cause of death, however, its pathomechanism has not been fully established yet. Growth differentiation factor 15 (GDF-15) is a chemokine secreted by activated macrophages in response to oxidative stress. It has now been shown that ischemic injury, mechanical stretch, and pro-inflammatory cytokines also stimulate the expression of GDF-15 in cardiac myocytes. The objective of this project is to describe the role of GDF-15 in the pathomechanism of acute right ventricle failure in the setting of acute pulmonary embolism and to verify the hypothesis that higher serum concentrations of GDF-15 are associated with more advanced right ventricle dysfunction and failure.
Study Type
OBSERVATIONAL
Enrollment
270
Department of Internal Medicine & Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw
Warsaw, Poland
hemodynamic deterioration
Hemodynamic deterioration defined according to ESC criteria as: change in blood pressure defined as: drop in systolic arterial blood pressure \< 90 mmHg or at least 40 mmHg, lasting ≤ than 15 minutes
Time frame: assessed daily through study completion, average of 10 days
Hemorrhagic complications
Major bleeding defined according to ISTH (International Society on Thrombosis and Haemostasis) criteria.
Time frame: assessed daily through study completion, average of 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.